{"id":"ustekinumab-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201835","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ustekinumab binds to the p40 subunit shared by IL-12 and IL-23, preventing these interleukins from activating T cells and other immune cells that drive chronic inflammatory diseases. By inhibiting these key cytokines, it suppresses the Th1 and Th17 pathways involved in autoimmune and inflammatory conditions.","oneSentence":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, reducing inflammatory immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:07.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT05092269","phase":"PHASE3","title":"A Long-term Extension Study of Ustekinumab in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-18","conditions":"Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic","enrollment":159},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT07310095","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","status":"RECRUITING","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2025-12-30","conditions":"Crohn Disease","enrollment":78},{"nctId":"NCT03466411","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-13","conditions":"Crohn's Disease","enrollment":1409},{"nctId":"NCT05083182","phase":"PHASE3","title":"A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-30","conditions":"Arthritis, Juvenile","enrollment":50},{"nctId":"NCT06425549","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-06-25","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":168},{"nctId":"NCT04673357","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-06","conditions":"Crohn Disease","enrollment":101},{"nctId":"NCT05029921","phase":"PHASE4","title":"A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-10","conditions":"Crohn Disease","enrollment":182},{"nctId":"NCT02648581","phase":"PHASE2","title":"Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-14","conditions":"Behçet Disease","enrollment":16},{"nctId":"NCT04978493","phase":"PHASE2","title":"A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-02","conditions":"Crohn Disease","enrollment":49},{"nctId":"NCT07152977","phase":"","title":"Description of the Radiological Response of Anoperineal Fistulizing Lesions of Crohn's Disease","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2019-07-31","conditions":"Anoperineal Lesions, Crohn's Disease Relapse","enrollment":52},{"nctId":"NCT07149467","phase":"PHASE3","title":"Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-09-10","conditions":"Crohn's Disease Aggravated, Crohn's Disease in Remission","enrollment":454},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT06738277","phase":"PHASE1","title":"This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-09","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":186},{"nctId":"NCT04524611","phase":"PHASE3","title":"Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-09-30","conditions":"Crohn's Disease (CD)","enrollment":527},{"nctId":"NCT04967508","phase":"PHASE3","title":"A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2021-07-06","conditions":"Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":503},{"nctId":"NCT04435600","phase":"PHASE3","title":"A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-07-14","conditions":"Psoriasis","enrollment":139},{"nctId":"NCT03782376","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2018-12-20","conditions":"Crohn Disease","enrollment":215},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02877134","phase":"PHASE2","title":"Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-25","conditions":"Crohn Disease","enrollment":388},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT04882072","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-09-15","conditions":"Takayasu Arteritis","enrollment":14},{"nctId":"NCT03107793","phase":"PHASE3","title":"Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2017-04-19","conditions":"Crohn Disease","enrollment":500},{"nctId":"NCT04816513","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-14","conditions":"Healthy","enrollment":300},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT04305327","phase":"PHASE3","title":"Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2022-12-07","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT05270733","phase":"PHASE4","title":"Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2022-11-10","conditions":"Psoriasis","enrollment":56},{"nctId":"NCT04533737","phase":"PHASE4","title":"Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2020-12-17","conditions":"Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis","enrollment":113},{"nctId":"NCT04549792","phase":"EARLY_PHASE1","title":"An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2021-04-01","conditions":"Ichthyosis","enrollment":13},{"nctId":"NCT02319759","phase":"PHASE2","title":"Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-03-27","conditions":"Psoriatic Arthritis","enrollment":149},{"nctId":"NCT04030533","phase":"PHASE1","title":"Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-29","conditions":"Healthy","enrollment":60},{"nctId":"NCT03362736","phase":"","title":"An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT06786507","phase":"","title":"A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Helwan University","startDate":"2025-05-15","conditions":"Ulcerative Colitis (UC)","enrollment":100},{"nctId":"NCT04607980","phase":"PHASE3","title":"A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-11-11","conditions":"Plaque Psoriasis","enrollment":563},{"nctId":"NCT03366142","phase":"PHASE1, PHASE2","title":"Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-02","conditions":"LAD1","enrollment":6},{"nctId":"NCT04245215","phase":"PHASE3","title":"Loss of RESponse to Ustekinumab Treated by Dose Escalation","status":"COMPLETED","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2020-03-11","conditions":"Crohn Disease","enrollment":108},{"nctId":"NCT06481215","phase":"PHASE1","title":"A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2022-03-11","conditions":"Healthy Volunteers","enrollment":122},{"nctId":"NCT04093531","phase":"PHASE1","title":"Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2020-01-15","conditions":"Primary Sjögren Syndrome","enrollment":12},{"nctId":"NCT01704534","phase":"PHASE2","title":"A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2012-05","conditions":"Hidradenitis Suppurativa","enrollment":20},{"nctId":"NCT04761627","phase":"PHASE3","title":"A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-03-24","conditions":"Psoriasis","enrollment":494},{"nctId":"NCT05861167","phase":"PHASE4","title":"SIIT Based on UST CDST in Patients With CD","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-06-01","conditions":"Crohn Disease","enrollment":140},{"nctId":"NCT04728360","phase":"PHASE3","title":"Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2021-07-06","conditions":"Plaque Psoriasis","enrollment":556},{"nctId":"NCT05705856","phase":"","title":"Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-02-15","conditions":"Crohn Disease","enrollment":200},{"nctId":"NCT04595409","phase":"PHASE3","title":"A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bioeq GmbH","startDate":"2020-11-09","conditions":"Plaque Psoriasis","enrollment":392},{"nctId":"NCT05720221","phase":"","title":"Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-07-15","conditions":"IBD","enrollment":100},{"nctId":"NCT04930042","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2021-06-03","conditions":"Psoriasis","enrollment":581},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT03881059","phase":"PHASE2","title":"Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-04-01","conditions":"Active Psoriatic Arthritis","enrollment":203},{"nctId":"NCT03553823","phase":"PHASE2","title":"Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-01-14","conditions":"Chronic Plaque-type Psoriasis","enrollment":40},{"nctId":"NCT04371185","phase":"PHASE1","title":"Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2020-08-08","conditions":"Psoriasis","enrollment":270},{"nctId":"NCT02684357","phase":"PHASE3","title":"BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":577},{"nctId":"NCT04996485","phase":"PHASE4","title":"Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children","status":"UNKNOWN","sponsor":"National Medical Research Center for Children's Health, Russian Federation","startDate":"2021-03-01","conditions":"Congenital Ichthyosis","enrollment":50},{"nctId":"NCT04428814","phase":"PHASE1","title":"Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-08-03","conditions":"Healthy Subjects","enrollment":271},{"nctId":"NCT02684370","phase":"PHASE3","title":"BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02","conditions":"Psoriasis","enrollment":560},{"nctId":"NCT02911116","phase":"PHASE2","title":"Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2017-03-30","conditions":"Uveitis","enrollment":8},{"nctId":"NCT04779762","phase":"NA","title":"Stelara and Diet Trial for Crohn\"s Disease","status":"UNKNOWN","sponsor":"Wolfson Medical Center","startDate":"2022-01","conditions":"Crohn Disease","enrollment":40},{"nctId":"NCT02561806","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10","conditions":"Plaque Psoriasis","enrollment":302},{"nctId":"NCT01713400","phase":"PHASE2","title":"Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-25","conditions":"Graft vs. Host Disease","enrollment":54},{"nctId":"NCT01708603","phase":"PHASE3","title":"P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-08","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":1831},{"nctId":"NCT01708629","phase":"PHASE3","title":"Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-09","conditions":"Plaque Psoriasis","enrollment":1881},{"nctId":"NCT02187172","phase":"PHASE4","title":"Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-07","conditions":"Psoriasis, Cardiovascular Disease","enrollment":43},{"nctId":"NCT02826603","phase":"PHASE3","title":"Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-22","conditions":"Plaque Psoriasis","enrollment":1114},{"nctId":"NCT01999868","phase":"PHASE2","title":"Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-03-19","conditions":"Psoriasis","enrollment":108},{"nctId":"NCT01806662","phase":"PHASE2","title":"Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2013-03","conditions":"Atopic Dermatitis","enrollment":32},{"nctId":"NCT02330380","phase":"","title":"Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2013-04","conditions":"Psoriasis, Inflammation","enrollment":26},{"nctId":"NCT02203032","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-10-07","conditions":"Psoriasis","enrollment":872},{"nctId":"NCT02074982","phase":"PHASE3","title":"Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-26","conditions":"Chronic Plaque Type Psoriasis","enrollment":676},{"nctId":"NCT01550744","phase":"PHASE3","title":"A Study of Ustekinumab to Evaluate a \"Subject-tailored\" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2012-03","conditions":"Psoriasis","enrollment":478},{"nctId":"NCT01369342","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-07","conditions":"Crohn's Disease, Inflammatory Bowel Disease, IBD","enrollment":640},{"nctId":"NCT01369329","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-07","conditions":"Crohn's Disease, IBD, Colitis","enrollment":769},{"nctId":"NCT01090063","phase":"NA","title":"Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2010-02","conditions":"Moderate to Severe Palmar Plantar Psoriasis","enrollment":26},{"nctId":"NCT01389973","phase":"PHASE2","title":"A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09","conditions":"Primary Biliary Cirrhosis","enrollment":20},{"nctId":"NCT02786732","phase":"PHASE3","title":"Study to Evaluate Broadlumab vs Placebo and Ustekinumab","status":"TERMINATED","sponsor":"MedDerm Associates","startDate":"2012-08","conditions":"Psoriasis","enrollment":15},{"nctId":"NCT01645280","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08","conditions":"Arthritis, Rheumatoid","enrollment":274},{"nctId":"NCT01945086","phase":"PHASE2","title":"A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2013-09","conditions":"Dermatitis, Atopic","enrollment":79},{"nctId":"NCT01511315","phase":"PHASE4","title":"The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-03","conditions":"Psoriasis","enrollment":36},{"nctId":"NCT00320216","phase":"PHASE2","title":"A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2003-11","conditions":"Psoriasis","enrollment":320},{"nctId":"NCT01009086","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-12","conditions":"Arthritis, Psoriatic","enrollment":615},{"nctId":"NCT01090427","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Psoriasis","enrollment":110},{"nctId":"NCT01276847","phase":"PHASE1","title":"A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03","conditions":"Psoriasis","enrollment":40},{"nctId":"NCT01059773","phase":"PHASE4","title":"A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2009-10","conditions":"Psoriasis","enrollment":490},{"nctId":"NCT01081704","phase":"PHASE1","title":"A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT01077362","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03","conditions":"Arthritis, Psoriatic","enrollment":312},{"nctId":"NCT00265122","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2004-04","conditions":"Crohn Disease","enrollment":131},{"nctId":"NCT01008995","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-10","conditions":"Psoriasis","enrollment":322},{"nctId":"NCT00267969","phase":"PHASE3","title":"A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2005-12","conditions":"Psoriasis","enrollment":766},{"nctId":"NCT01091051","phase":"PHASE3","title":"Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis","status":"TERMINATED","sponsor":"Innovaderm Research Inc.","startDate":"2010-03","conditions":"Palmo-Plantar Pustular Psoriasis, Palmo-Plantar Pustulosis","enrollment":33},{"nctId":"NCT00267956","phase":"PHASE2","title":"An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Psoriatic Arthritis","enrollment":146},{"nctId":"NCT00307437","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2005-05","conditions":"Psoriasis","enrollment":1230},{"nctId":"NCT00454584","phase":"PHASE3","title":"An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2007-03","conditions":"Psoriasis","enrollment":903},{"nctId":"NCT00207727","phase":"PHASE2","title":"A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2004-07","conditions":"Multiple Sclerosis","enrollment":249}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ustekinumab Injection","genericName":"Ustekinumab Injection","companyName":"National Medical Research Center for Children's Health, Russian Federation","companyId":"national-medical-research-center-for-children-s-health-russian-federation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ustekinumab is an interleukin-12 inhibitor, classified as an antibody inhibitor, used to treat various conditions including Crohn's disease, arthritis, and ulcerative colitis. It is marketed under the brand name Stelara and is administered via injection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}